Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (Nov 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 5, 2025
Period End
November 5, 2025
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) reported third quarter 2025 results on November 5, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K.

Portfolio Receipts grew 11% to $814 milliona, Royalty Receipts grew 11% to $811 million, and net cash provided by operating activities was $703 million. Adjusted EBITDA (non-GAAP) was $779 million and Portfolio Cash Flow (non-GAAP) was $657 million for the quarter. The company raised its full-year 2025 Portfolio Receipts guidance to $3,200 million to $3,250 million, from the previous $3,050 million to $3,150 million, representing expected growth of 14% to 16% versus the previously expected 9% to 12%.

The guidance excludes contributions from transactions announced after the release date. Management also expects 2025 interest paid of approximately $275 millionb and 2026 interest paid of approximately $350 to $360 million. Capital deployment was $1.0 billion in the third quarter and $1.7 billion for the first nine months of 2025, and management cited new transactions of up to $3.8 billion announced during 2025.

The company issued $2.0 billionc of senior unsecured notes in September 2025 and repaid $1.0 billion of notes at maturity in August 2025. Share repurchases totaled $152 million in the quarter and $1.2 billion year to date, and cash and cash equivalents were $939 million as of September 30, 2025.

02—Key points

Key Highlights

  1. Portfolio Receipts rose 11% to $814 million in Q3 2025, driven primarily by Voranigo, Tremfya and the cystic fibrosis franchise.
  2. Full-year 2025 Portfolio Receipts guidance was raised to $3,200 million to $3,250 million, from $3,050 million to $3,150 million.
  3. Capital Deployment was $1.0 billion in Q3 2025 and $1.7 billion for the first nine months of 2025.
  4. New transactions included an up to $950 million Imdelltra royalty from Amgen, up to $300 million obexelimab funding with Zenas BioPharma, and a $310 million Amvuttra royalty from Alnylam.
  5. Total debt principal was $9.2 billion as of September 30, 2025, with a weighted-average cost of debt of 3.75% and weighted-average duration of approximately 13 years on the $8.8 billion of unsecured notes.
  6. Share repurchases were $152 million in Q3 2025 and $1.2 billion in the first nine months of 2025, under a program authorizing up to $3.0 billion.
  7. Adjusted EBITDA rose 15% to $779 million, while Portfolio Cash Flow rose 6% to $657 million; net cash from operating activities was flat at $703 million.

03—Questions

Frequently Asked Questions

  1. How did Royalty Pharma's third quarter 2025 revenue perform?

    Portfolio Receipts increased 11% to $814 million from $735 million in Q3 2024, and Royalty Receipts increased 11% to $811 million from $732 million. The growth was primarily driven by Voranigo, Tremfya and the cystic fibrosis franchise.

  2. Why did the company raise its 2025 guidance?

    Royalty Pharma raised its full-year 2025 Portfolio Receipts guidance to $3,200 million to $3,250 million, from $3,050 million to $3,150 million. The guidance excludes contributions from transactions announced after the release date.

  3. What major transactions did the company complete recently?

    The company acquired a royalty on Amgen's Imdelltra for up to $950 million, entered a funding agreement on obexelimab with Zenas BioPharma for up to $300 million, and acquired a royalty on Alnylam's Amvuttra for $310 million. The filing notes the Amvuttra acquisition was completed in November 2025.

  4. How is the company's debt position and interest burden changing?

    As of September 30, 2025, total debt principal was $9.2 billion, including $2.0 billion of senior unsecured notes issued in September 2025 with a weighted-average coupon of 5.16%. Interest paid is expected to be approximately $275 million in 2025 and approximately $350 to $360 million in 2026.

  5. What do the non-GAAP measures Adjusted EBITDA and Portfolio Cash Flow indicate?

    Adjusted EBITDA was $779 million in Q3 2025, calculated as Portfolio Receipts minus payments for operating and professional costs. Portfolio Cash Flow was $657 million, calculated as Adjusted EBITDA minus net interest paid. These measures are defined under the credit agreement and are reconciled to net cash provided by operating activities in the filing.

04—Continue

← View all 8-K filings